ARTICLE | Clinical News

Lirilumab: Phase II ongoing

October 10, 2016 7:00 AM UTC

A DSMB recommended for the seventh time continuation of the double-blind, placebo-controlled, French Phase II EffiKIR trial evaluating 0.1 and 1 mg/kg lirilumab based on a safety analysis. The trial completed enrollment of about 150 patients in 2014. ...